BROWSE·page 517 of 605

Browse EX-10 agreements

7,251 matching material contract exhibits.


EX-10.1

CASEYS GENERAL STORES INC

Document

EXHIBIT 10.1

RESTRICTED STOCK UNITS AGREEMENT

(LTI Awards to Officers – Time-Based RSUs)

This Restricted Stock Units Agreement (this “Agreement”) is made and entered into on [●] (the “Grant Date”), pursuant to the Casey’s General Stores, Inc. 2025 Stock Incentive Plan (the “Plan”). The Compensation and Human Capital Committee (the “Committee”) has selected the party below (such party, the “Participant”) to receive the award described herein (the “Award”) of Restricted Stock Units, each of which represents the right to receive on the applicable settlement date (each a “Settlement Date”) one (1) share of the Common Stock, no par value (“Stock”) of Casey’s General Stores, Inc., an Iowa corporation (the “Company”), on the terms and conditions set forth below to which Participant accepts and agrees:

1.Award Granted. On the Grant Date, the Participant shall acquire, subject to the provisions of this Agreement, the number of Restricted Stock Units as specified below (the “Units”).

Participant:                [●]

Grant Date:                [●]

…

EX-10.1·8-K·CIK 726958·ACC 0000726958-26-000033·Filed Jun 09, 2026, 16:30 ET

EX-10.3

CASEYS GENERAL STORES INC

Document

EXHIBIT 10.3

RESTRICTED STOCK UNITS AGREEMENT

(LTI Awards to Officers – Performance-Based RSUs [EBITDA])

This Restricted Stock Units Agreement (this “Agreement”) is made and entered into on [●] (the “Grant Date”), pursuant to the Casey’s General Stores, Inc. 2025 Stock Incentive Plan (the “Plan”). The Compensation and Human Capital Committee (the “Committee”) has selected the party below (such party, the “Participant”) to receive the award described herein (the “Award”) of Performance-Based Restricted Stock Units, each of which represents the right to receive on the applicable settlement date (each a “Settlement Date”) one (1) share of the Common Stock, no par value (“Stock”) of Casey’s General Stores, Inc., an Iowa corporation (the “Company”), on the terms and conditions set forth below to which Participant accepts and agrees:

1.Award Granted. On the Grant Date, the Participant shall acquire, subject to the provisions of this Agreement, the target number of Performance-Based Restricted Stock Units as specified below (the “Units”).

…

EX-10.3·8-K·CIK 726958·ACC 0000726958-26-000033·Filed Jun 09, 2026, 16:30 ET

EX-10.1

AFFILIATED MANAGERS GROUP, INC.

Execution Version

Deal CUSIP No. 008253AX4

Revolver CUSIP No. 008253AY2

FOURTH AMENDED AND RESTATED CREDIT AGREEMENT

Dated as of June 9, 2026

among

AFFILIATED MANAGERS GROUP, INC.,

as Borrower,

BANK OF AMERICA, N.A.,

as Administrative Agent, Swingline Lender and L/C Issuer

and

the Several Lenders

from Time to Time Parties Hereto

and

BOFA SECURITIES, INC.,

CITIZENS BANK, N.A.

and

WELLS FARGO SECURITIES, LLC

as Joint Book Runners and Joint Lead Arrangers,

and

BARCLAYS BANK PLC,

CITIBANK, N.A.,

JPMORGAN CHASE BANK, N.A.,

MORGAN STANLEY SENIOR FUNDING, INC.,

ROYAL BANK OF CANADA,

and

MANUFACTURERS & TRADERS TRUST COMPANY,

as Joint Lead Arrangers,

and

BOFA SECURITIES, INC.,

CITIZENS BANK, N.A.

and

WELLS FARGO SECURITIES, LLC,

as Co-Syndication Agents,

and

BARCLAYS BANK PLC,

CITIBANK, N.A.,

JPMORGAN CHASE BANK, N.A.,

MORGAN STANLEY SENIOR FUNDING, INC.,

ROYAL BANK OF CANADA,


MANUFACTURERS & TRADERS TRUST COMPANY,

and

…

EX-10.1·8-K·CIK 1004434·ACC 0001193125-26-263845·Filed Jun 09, 2026, 16:30 ET

Execution Version

 

NOTE PURCHASE AGREEMENT

 

This NOTE PURCHASE AGREEMENT (the “Agreement”), dated as of June 3, 2026, is by and among Aditxt, Inc., a Delaware corporation with offices located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043 (the “ADTX Borrower”), Ignite Proteomics LLC, a Delaware limited liability company (“Ignite Borrower”, and together with the ADTX Borrower, the “Borrowers”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). The Buyers and the Borrowers are sometimes referred to herein collectively as the “Parties” and individually as a “Party”.

 

RECITALS

…

EX-10.1·8-K·CIK 1726711·ACC 0001213900-26-066823·Filed Jun 09, 2026, 16:30 ET

Execution Version

 

SECURITY AND PLEDGE AGREEMENT

SECURITY AND PLEDGE AGREEMENT, dated as of June 3, 2026, is by and among Ignite Proteomics LLC, a Delaware limited liability company with offices located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043 (the “Company”), and each of the undersigned direct and indirect and direct Subsidiaries (as defined below) of the Company from time to time, if any (each a “Grantor” and together with the Company, collectively, the “Grantors”), in favor of [●] with offices located at [●], in its capacity as collateral agent (together with its successors and assignees, in such capacity, the “Collateral Agent”) for the Noteholders (as defined below) party to the Note Purchase Agreement (as defined below).

W I T N E S S E T H:

…

EX-10.3·8-K·CIK 1726711·ACC 0001213900-26-066823·Filed Jun 09, 2026, 16:30 ET

Execution Copy

 

[FORM OF SENIOR SECURED PROMISSORY NOTE]

THE ISSUANCE AND SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE BORROWERS), IN A FORM REASONABLY ACCEPTABLE TO THE BORROWERS, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO THE TERMS HEREOF.

…

EX-10.2·8-K·CIK 1726711·ACC 0001213900-26-066823·Filed Jun 09, 2026, 16:30 ET

Execution Version

 

PLEDGE AGREEMENT

PLEDGE AGREEMENT, dated as of June 3, 2026 (this “Agreement”), made by Aditxt, Inc., a Delaware corporation (the “Pledgor”) with offices located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043, in favor of [●], with offices located at [●], in its capacity as collateral agent (together with its successors and assignees, in such capacity, the “Collateral Agent”) for the Noteholders (as defined below) party to the Note Purchase Agreement (as defined below).

W I T N E S S E T H:

…

EX-10.4·8-K·CIK 1726711·ACC 0001213900-26-066823·Filed Jun 09, 2026, 16:30 ET

MOONLAKE IMMUNOTHERAPEUTICS

AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN

 

Purpose

 

The purpose of this MoonLake Immunotherapeutics 2022 Amended and Restated Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the best available employees for positions of substantial responsibility and to motivate Participants to optimize the profitability and growth of the Company through incentives that are consistent with the Company’s goals and that link the personal interests of Participants to those of the Company’s shareholders. The Plan provides for the grant of Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock and Other Share-Based Awards and for Incentive Bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the Com

…

EX-10.1·8-K·CIK 1821586·ACC 0001213900-26-066821·Filed Jun 09, 2026, 16:30 ET

EX-10.2

Ingredion Inc

exhibit10-2xcoxoperation

Co-operation Agreement Relating to the takeover offer for the entire issued and to be issued share capital of Tate & Lyle plc Dated 8 June 2026 TATE & LYLE PLC and INGREDION INCORPORATED Ref: L-371397 EXHIBIT 10.2


 

3222356760 i Contents Page 1 Interpretation ......................................................................................................................... 1 2 Effective Date and Terms of the Acquisition .......................................................................... 7 3 Undertakings in relation to Regulatory Conditions ................................................................ 8 4 Target Documentation ......................................................................................................... 12 5 Qualifications ....................................................................................................................... 12 6 Implementation .................................................................................................................... 13 7 Switching to an Offer ......

…

EX-10.2·8-K·CIK 1046257·ACC 0001628280-26-041921·Filed Jun 09, 2026, 16:25 ET

EX-10.3

Ingredion Inc

exhibit10-3xshareholderi

\\1093970 4129-7280-9064 v4 Hogan Lovells DEED OF IRREVOCABLE UNDERTAKING INSTITUTIONAL SHAREHOLDER To: Ingredion Incorporated ("Ingredion") 5 Westbrook Corporate Center Westchester IL 60154 USA 8 June 2026 Dear Sirs, RECOMMENDED CASH OFFER FOR TATE & LYLE PLC ("TATE & LYLE") BY INGREDION INCORPORATED We understand that Ingredion intends to acquire the entire issued and to be issued ordinary share capital of Tate & Lyle (the "Acquisition") by way of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Companies Act") (including any new, increased, renewed or revised scheme of arrangement the terms of which are no less favourable to shareholders of Tate & Lyle as the terms set out in the Rule 2.7 Announcement., the "Scheme") substantially on the terms (including, for the avoidance of doubt, at a price of at least 595 pence in cash per ordinary share plus the right to receive and retain 2026 Final Dividend (as defined in the Rule 2.7 Announcement) of 13.2 pence per ordinary share and the 2027 Interim Dividend (as defined in the Rule 2.7 Anno

…

EX-10.3·8-K·CIK 1046257·ACC 0001628280-26-041921·Filed Jun 09, 2026, 16:25 ET

EX-10.5

Ingredion Inc

exhibit10-5xbridgecredit

Execution Version 364-DAY BRIDGE LOAN AGREEMENT dated as of June 8, 2026 among INGREDION INCORPORATED, The LENDERS Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent __________________________ JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Arranger EXHIBIT 10.5


 

i TABLE OF CONTENTS Page ARTICLE I Definitions ................................................................................................................................ 1 SECTION 1.01. Defined Terms ................................................................................................. 1 SECTION 1.02. Classification of Loans and Borrowings ....................................................... 32 SECTION 1.03. Terms Generally ............................................................................................ 32 SECTION 1.04. Accounting Terms; GAAP ............................................................................ 33 SECTION 1.05. Interest Rates; Benchmark Notification ...................................

…

EX-10.5·8-K·CIK 1046257·ACC 0001628280-26-041921·Filed Jun 09, 2026, 16:25 ET

EX-10.1

Ingredion Inc

exhibit10-1xrule27announ

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION 8 June 2026 RECOMMENDED CASH ACQUISITION of TATE & LYLE PLC ("TATE & LYLE") by INGREDION INCORPORATED ("INGREDION") to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Summary • The boards of Ingredion and Tate & Lyle are pleased to announce that they have reached agreement on the terms and conditions of a recommended cash offer by Ingredion for the entire issued and to be issued ordinary share capital of Tate & Lyle (the "Acquisition"). • Under the terms of the Acquisition, Tate & Lyle Shareholders will be entitled to receive in aggregate: o 595 pence in cash per Tate & Lyle Share (the "Cash Consideration"); plus o a final dividend in relation to the financial year ended 31 March 2026 of no greater than 13.2 pence per ordinary Tat

…

EX-10.1·8-K·CIK 1046257·ACC 0001628280-26-041921·Filed Jun 09, 2026, 16:25 ET